Literature DB >> 2118845

IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA.

T Pressler1, S S Pedersen, F Espersen, N Høiby, C Koch.   

Abstract

ELISAs using subclass-specific monoclonal antibodies were developed for the quantification of human IgG1, IgG2, IgG3 and IgG4 antibodies to Ps. aeruginosa. We investigated the pattern of IgG subclass antibodies against Ps. aeruginosa in serum from patients with cystic fibrosis (CF), other patients with chronic Ps. aeruginosa infection, and healthy controls. Healthy controls and patients with CF but without Ps. aeruginosa infection showed no or very low titres of antibodies against Ps. aeruginosa. In the early stage of chronic Ps. aeruginosa infection, antibody titres in all four subclasses were significantly higher than either normals or CF patients without infection. Other patients with Ps. aeruginosa infection showed the same increased level of IgG subclass antibodies as CF patients in an early stage of infection. Sixteen patients (eight in good and eight in poor clinical condition) have been followed for an average of 13 years with multiple serum samples covering the pre-infection, early and late stages of chronic infection. Patients in a poor clinical condition showed significantly higher levels of IgG3 antibodies in the first year of infection and 2 years later also had significantly higher IgG2 antibody levels. We conclude that elevated levels of IgG2 and IgG3 antibodies to Ps. aeruginosa are a sign of poor prognosis in CF.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118845      PMCID: PMC1534976          DOI: 10.1111/j.1365-2249.1990.tb05351.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis.

Authors:  T R Shryock; J S Mollé; J D Klinger; M J Thomassen
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

2.  Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  R B Fick; J Olchowski; S U Squier; W W Merrill; H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1986-03

3.  "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin.

Authors:  A Forsgren; J Sjöquist
Journal:  J Immunol       Date:  1966-12       Impact factor: 5.422

Review 4.  IgG4 and the immune system.

Authors:  L Perelmutter
Journal:  Clin Rev Allergy       Date:  1983-06

5.  Correlations between the concentrations of the four sub-classes of IgG and Gm Allotypes in normal human sera.

Authors:  A Morell; F Skvaril; A G Steinberg; E Van Loghem; W D Terry
Journal:  J Immunol       Date:  1972-01       Impact factor: 5.422

6.  Serotyping of Pseudomonas aeruginosa. 2. Results of an O group classification.

Authors:  O S Mikkelsen
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1970

7.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.

Authors:  R B Fick; G P Naegel; S U Squier; R E Wood; J B Gee; H Y Reynolds
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Functional activity of different IgG subclass antibodies against type b capsular polysaccharide of Haemophilus influenzae.

Authors:  G A Weinberg; D M Granoff; M H Nahm; P G Shackelford
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

9.  Hypergammaglobulinemia in cystic fibrosis. Role of Pseudomonas endobronchial infection.

Authors:  R B Moss
Journal:  Chest       Date:  1987-04       Impact factor: 9.410

10.  IgG2 subclass restriction of antibody to pneumococcal polysaccharides.

Authors:  D J Barrett; E M Ayoub
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

View more
  17 in total

1.  Pseudomonas serology: confusion, controversy, and challenges.

Authors:  P M Farrell; J R W Govan
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

2.  Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.

Authors:  T D Petersen; O Ciofu; T Pressler; B Giwercman; S S Pedersen; N Høiby
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

3.  Pigeon breeders' lung; IgG subclasses to pigeon intestinal mucin and IgA antigens.

Authors:  A Todd; R Coan; A Allen
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

4.  Specific IgG subclass antibody pattern to Aspergillus fumigatus in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA).

Authors:  M Skov; T Pressler; H E Jensen; N Høiby; C Koch
Journal:  Thorax       Date:  1999-01       Impact factor: 9.139

5.  Immunoproteomics to examine cystic fibrosis host interactions with extracellular Pseudomonas aeruginosa proteins.

Authors:  Hamish G Upritchard; Stuart J Cordwell; Iain L Lamont
Journal:  Infect Immun       Date:  2008-07-28       Impact factor: 3.441

6.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

7.  Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

Authors:  G Kronborg; T Pressler; A Fomsgaard; C Koch; N Høiby
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

8.  Determination of IgG subclass antibodies to Pseudomonas aeruginosa outer membrane proteins in cystic fibrosis lung infection using immunoblotting and enzyme-linked immunosorbent assay.

Authors:  T Pressler; G Kronborg; G H Shand; B Mansa; N Høiby
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

9.  Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.

Authors:  T Pressler; J P Pandey; F Espersen; S S Pedersen; A Fomsgaard; C Koch; N Høiby
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

10.  A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Authors:  Eric T Weimer; Haiping Lu; Nancy D Kock; Daniel J Wozniak; Steven B Mizel
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.